1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Pa Shun International Holdings Limited

Pa Shun International Holdings Limited

HHKEX:574
0.02
HKD
+0.00
(-10.00%)
59.00MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.86
1.22
0.84
0.65
0.66
0.56
0.44
0.24
0.04
0.04
0.07
0.04
0.06
- -
Basic EPS, GAAP
0.07
0.07
0.09
0.01
0.01
-0.04
-0.1
-0.22
-0.17
-0.02
- -
-0.01
-0.01
- -
Free Cash Flow per Basic Share
0.05
0.04
-0.05
-0.01
-0.1
-0.01
-0.03
-0.01
-0.01
- -
-0.02
- -
-0.01
- -
Dividend per Share
- -
- -
- -
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.11
0.14
0.55
0.55
0.53
0.49
0.36
0.14
-0.03
-0.06
-0.06
-0.07
-0.08
-0.08
Tangible Book Value per Share
-0.12
0.13
0.55
0.55
0.53
0.48
0.34
0.13
-0.03
-0.06
-0.06
-0.07
-0.08
-0.08
Basic Weighted Avg Shares
926
692
1,028
1,318
1,327
1,472
1,908
1,944
1,944
1,944
1,944
1,944
1,475
1,944
Sales/Revenue/Turnover
794
847
868
861
870
821
845
475
86
72
129
87
87
- -
Operating Margin (%)
12.79
13.75
12.27
5.73
4.04
-1.18
-0.44
-3.4
-17.15
-7.06
16.88
-7
4.01
- -
Depreciation Expense
4
10
10
8
6
6
7
7
6
4
3
3
3
- -
Net Income, GAAP
63
46
88
8
10
-59
-194
-418
-330
-43
2
-15
-16
- -
Effective Tax Rate (%)
22.44
35.82
24.88
73.01
47.82
- -
- -
- -
- -
- -
31.04
- -
- -
- -
Profit Margin (%)
7.94
5.42
10.17
0.89
1.17
-7.23
-22.91
-88.13
-384.58
-60.43
1.82
-17.69
-18.27
- -
Working Capital
48
107
557
636
536
681
440
-2
-149
-186
-124
1
-17
-17
LT Debt
- -
- -
- -
132
69
82
64
1
- -
- -
51
29
20
20
Total Equity
-149
181
723
725
749
856
684
278
-59
-116
-116
-136
-148
-148
Return on Invested Capital (%)
- -
60.52
12.15
0.93
1.34
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-72.32
61.98
19.33
1.01
1.97
- -
- -
- -
- -
- -
52.33
- -
- -
- -
Return on Common Equity (%)
- -
- -
19.5
1.06
1.38
-7.33
-24.71
-85.8
- -
- -
- -
- -
- -
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
15
- -
26
LT Borrowings
29
- -
20
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,944
1,944
1,944
Market Capitalization
65
39
53

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
105
- -
101
Cash, Cash Equivalents & STI
16
- -
6
Accounts Receivable, Net
26
- -
52
Inventories
38
- -
20
Total Current Liabilities
104
- -
118
Payables & Accruals
- -
- -
- -
ST Debt
15
- -
26
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.87%
0.57%
8.78%
Free Cash Flow
376.38%
432.34%
534.87%
Net Income, GAAP
-136.18%
-192.28%
3.55%
Sales/Revenue/Turnover
-9.71%
-10.18%
0.29%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
129
2024
- -
- -
87
2025
- -
- -
87

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
-0.01
2025
- -
- -
-0.01

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Qing hai Ma
Full Time Employees
108
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Shui On Centre Hong Kong Hong Kong
IPO Date
Jun 19, 2015
Website
pashun.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pa Shun International Holdings Limited is an investment holding company engaged in the pharmaceutical distribution and manufacturing business primarily in the People's Republic of China. The company operates through two main segments: the Pharmaceutical Distribution segment, which sells pharmaceutical products to wholesalers, hospitals, and other medical institutions in rural areas; and the Pharmaceutical Manufacturing segment, which manufactures and sells pharmaceutical products produced by the company. It targets healthcare providers and institutions in southwestern China, with approximately 90 to 106 employees serving these markets. Incorporated in 2011 and headquartered at Suites 2601-2603, 26/F, Shui On Centre, 6-8 Harbour Road, Wan Chai, Hong Kong, the company is a subsidiary of Praise Treasure Limited and was formerly known as Pa Shun Pharmaceutical International Holdings Limited, changing its name in June 2017. Recent developments include reporting a loss for the year ended December 31, 2024, attributable to equity holders of approximately RMB15,313,000 on revenue of RMB86,554,000, compared to a profit of RMB2,350,000 on higher revenue of RMB129,430,000 in 2023; a net liability position of approximately RMB136,036,000 as of December 31, 2024, amid ongoing repayment obligations under a scheme of arrangement; and a half-year loss for the period ended June 30, 2025, with delays in publishing full 2024 annual results and audit completion into 2025. In February 2025, the Stock Exchange of Hong Kong issued disciplinary actions against two former directors, Mr. Chen Yen Fei and Mr. Shen Shun, related to past conduct. No major acquisitions, partnerships, funding rounds, or new product launches have been reported in the last 1-2 years.